ArticleMedicina (Kaunas, Lithuania)2020
Epithelial-Mesenchymal Transition: A Major Pathogenic Driver in Idiopathic Pulmonary Fibrosis?
Article in Medicina (Kaunas, Lithuania), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Use quercetin for pulmonary fibrosis: a preclinical systematic review and meta-analysis.Inflammopharmacology · 2025Pooled it
- The Role of Lung Microbiome in Fibrotic Interstitial Lung Disease-A Systematic Review.Biomolecules · 2024Pooled it
- Traditional Chinese Medicine Ion Introduction Therapy Reduces the Incidence of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study.International journal of general medicine · 2025Trial
- Pharmacological activation of dopamine receptor D1 attenuates TGF-β-induced epithelial-mesenchymal transition in A549 and BEAS-2B cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Testing the Possible Protective Effect of Ivermectin on Bleomycin-Induced Pulmonary Fibrosis in Albino Rats: Histological and Immunohistochemical Study.Medicina (Kaunas, Lithuania) · 2026Article
- An hiPSC-derived multi-lineage lung model exhibiting proximal-distal epithelial features for modeling pulmonary fibrosis.Frontiers in cell and developmental biology · 2026Article
- Targeting the epithelium in pulmonary fibrosis.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- TRIM2 exacerbates the advancement of idiopathic pulmonary fibrosis by modulating β-catenin and endoplasmic reticulum stress.European journal of medical research · 2025Article
- Loss of Ubiquitin-Specific Protease 11 Mitigates Pulmonary Fibrosis in Human Pluripotent Stem Cell-Derived Alveolar Organoids.International journal of stem cells · 2025Article
- Proteome-wide mendelian randomization identifies causal plasma proteins in interstitial lung disease.Scientific reports · 2025Article
- The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.Cell communication and signaling : CCS · 2024Review
- The providing multidisciplinary ILD diagnoses (PROMISE) study - study design of the national registry of Japan facilitating interactive online multidisciplinary discussion diagnosis.BMC pulmonary medicine · 2024Article
- Cepharanthine attenuates pulmonary fibrosis via modulating macrophage M2 polarization.BMC pulmonary medicine · 2024Article
- Blood lipid profiles as a prognostic biomarker in idiopathic pulmonary fibrosis.Respiratory research · 2024Article
- Novel AT2 Cell Subpopulations and Diagnostic Biomarkers in IPF: Integrating Machine Learning with Single-Cell Analysis.International journal of molecular sciences · 2024Article
- Pirfenidone in Idiopathic Pulmonary Fibrosis: Real-World Observation on Efficacy and Safety, Focus on Patients Undergoing Antithrombotic and Anticoagulant.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Prognostic Function and Immunologic Landscape of a Predictive Model Based on Five Senescence-Related Genes in IPF Bronchoalveolar Lavage Fluid.Biomedicines · 2024Article
- Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Structural Modification and Optimisation of Hyperoside Oriented to Inhibit TGF-β-Induced EMT Activity in Alveolar Epithelial Cells.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Vascular Endothelial Damage in COPD: Where Are We Now, Where Will We Go?Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the fact that epithelial-mesenchymal transition (EMT) is a common downstream mechanism of all fibrosing diseases, whether it represents a leading process in the development of idiopathic pulmonary fibrosis has been widely discussed and is still a matter of debate. According to the most recent advances, EMT is thought to be mainly driven by the overexpression of several developmental pathways upstream of dysfunctional epithelial regeneration, which indeed normally occurs after damage and during tissue turnover. Future research should likely be directed at investigating the molecular mechanisms underlying epithelial dysfunction, in order to allow for both the removal of the wording "idiopathic" from idiopathic pulmonary fibrosis ("IPF") and for the identification of earlier and more effective therapeutic targets than the late process of fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.